2016
DOI: 10.18632/aging.101044 View full text |Buy / Rent full text
|
|

Abstract: Prostate cancer management is complicated by extreme disease heterogeneity, which is further limited by availability of prognostic biomarkers. Recognition of prostate cancer as a genetic disease has prompted a focus on the nuclear genome for biomarker discovery, with little attention given to the mitochondrial genome. While it is evident that mitochondrial DNA (mtDNA) mutations are acquired during prostate tumorigenesis, no study has evaluated the prognostic value of mtDNA variation. Here we used next-generati… Show more

Help me understand this report

Search citation statements

Order By: Relevance
0
0
0
0
0
2
24
0

Publication Types

Select...

Relationship

0
0

Authors

Journals